Evidence map›Paper›PMID 40530722›Full record

ReviewCurrent topics in medicinal chemistry2026

Antibody-aptamer Complementation: Advancing Biosensing for Disease Monitoring.

Thangavel Lakshmipriya, Subash C B Gopinath

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thangavel LakshmipriyaCenter for Global Health Research, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai - 602 105, Tamil Nadu, India.
Subash C B GopinathInstitute of Nano Electronic Engineering, Universiti Malaysia Perlis (UniMAP), 01000 Kangar, Perlis, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A biosensor is a biological device designed to convert biological responses into an electrical signal, which has diverse applications across various fields, including diagnostics, environmental monitoring, food safety, and drug discovery. Among these, biosensing technology has achieved remarkable success in medical diagnostics. To detect target molecules for various probe molecules, such as nucleic acids, peptides, antibodies, and proteins are widely used. Of these, antibodies are well-established as remarkable molecules for detecting and monitoring a broad range of analytes. Recently, a novel class of molecules known as aptamers, often referred to as "artificial antibodies," has gained significant attention from researchers for numerous biomedical applications, particularly in biosensing. Aptamers are synthetic molecules generated through a method called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Since aptamer and antibody have different bindings for target molecules, various biosensing techniques are utilized by using the combination of aptamer and antibody to enhance the biosensor. This combination possesses a unique and beneficial feature and holds the potential to drive significant advancements in sensing technology. Applying these combinations in biosensing technologies has some limitations due to the aptamer generation for some particular targets. This review explores recent applications of antibodies, aptamers, and their combined use in enhancing biosensing technologies and their limitations.

Indexed as

AntibodiesAptamers, NucleotideBiosensing TechniquesAnimalsHumansSELEX Aptamer TechniqueAntibodiesAptamers, NucleotideAntibodyAptamerBiosensing TechnologiesBiosensorImmunosensorSELEX

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.